Oxford BioDynamics
Oxford BioDynamics to Raise £12.0M in Stock Placement, Offering
The company said it will use the proceeds of the transactions, which are subject to shareholder approval, to advance its EpiSwitch diagnostics platform.
Oxford BioDynamics Awarded Grant to Apply EpiSwitch to ICI Cancer Therapy Response
The two-year PACT grant will fund the application of the EpiSwitch technology to the analysis of primary and acquired ICI resistance in several clinical trials.
Agilent, Oxford BioDynamics Sign Supply, Resale Agreement for Array Kit
Agilent will supply a custom-made SurePrint G3CGH Microarray for Oxford's newly launched Explorer Array Kit, which will include OBD's 3D Genome Probes.
The partners aim to identify signatures to predict the severity of disease in those infected and determine how patients will respond to therapies.
Dec 12, 2018
Oxford Biodynamics Posts Flat Revenues for FY 2018
Nov 12, 2018
Oxford BioDynamics Forms Autism Biomarker Alliance
Oct 10, 2017